Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lipton, A.
Right arrow Articles by Carney, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipton, A.
Right arrow Articles by Carney, W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 10 (May), 2003: 1967-1972
© 2003 American Society for Clinical Oncology

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

A. Lipton, S.M. Ali, K. Leitzel, L. Demers, H.A. Harvey, H.A. Chaudri-Ross, C. Brady, P. Wyld, W. Carney

From the Milton S. Hershey Medical Center, Hershey, PA; Veterans Affairs Medical Center, Lebanon, PA; Novartis Pharmaceutical Corporation, East Hanover, NJ; Bayer Corporation, Tarrytown, New York; and Novartis Pharma AG, Basel, Switzerland.

Address reprint requests to Allan Lipton, MD, Penn State Milton S. Hershey Medical Center, Department of Medicine, Division of Hematology/Oncology HO46, 500 University Dr, PO Box 850, Hershey, PA 17033; email: alipton{at}psu.edu.

Purpose: To determine the effect of elevated serum HER-2/neu on the response of metastatic breast cancer patients to an aromatase inhibitor versus an antiestrogen.

Patients and Methods: Five hundred sixty-two estrogen receptor–positive metastatic breast cancer patients were randomized to first-line hormone therapy with either letrozole or tamoxifen. An automated enzyme-linked immunosorbent assay was used to detect serum HER-2/neu.

Results: For patients with normal serum HER-2/neu (70.5%), objective response rate (ORR; 39% in letrozole-treated patients v 26% in tamoxifen-treated patients; P = .008), clinical benefit (CB; 57% v 45%; P = .016), time to progression (TTP; median, 12.2 v 8.5 months; P = .0019), and time to treatment failure (TTF; median, 11.6 v 6.2 months; P = .0066) were significantly better in patients treated with letrozole. In the elevated HER-2/neu group (29.5%), there was no significant difference in ORR (17% in letrozole-treated patients v 13% in tamoxifen-treated patients; P = .45) or CB (33% v 26%; P = .31), but there was a strong trend in favor of a longer TTP with letrozole (median, 6.1 v 3.3 months; P = .0596) and a significantly longer TTF with letrozole (median, 6.0 v 3.2 months; P = .0418). Multivariate analysis revealed that elevated serum HER-2/neu was a negative predictor for ORR and TTP.

Conclusion: Patients with normal serum HER-2/neu receiving letrozole demonstrated a significantly greater ORR and CB and longer TTP and TTF than patients receiving tamoxifen. Although in patients with elevated serum HER-2/neu there was no significant difference between letrozole and tamoxifen in ORR or CB, there was a strong trend favoring longer TTP and significantly longer TTF with letrozole.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JCOHome page
B. Kaufman, J. R. Mackey, M. R. Clemens, P. P. Bapsy, A. Vaid, A. Wardley, S. Tjulandin, M. Jahn, M. Lehle, A. Feyereislova, et al.
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
J. Clin. Oncol., November 20, 2009; 27(33): 5529 - 5537.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Johnston, J. Pippen Jr, X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H. L. Gomez, G. Romieu, A. Manikhas, M. J. Kennedy, et al.
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
J. Clin. Oncol., November 20, 2009; 27(33): 5538 - 5546.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Cortes and J. Baselga
How to Treat Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Amplified Breast Cancer
J. Clin. Oncol., November 20, 2009; 27(33): 5492 - 5494.
[Full Text] [PDF]


Home page
JCOHome page
R. S. Finn, R. Gagnon, A. Di Leo, M. F. Press, M. Arbushites, and M. Koehler
Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study
J. Clin. Oncol., November 20, 2009; 27(33): 5552 - 5558.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. U. Buzdar
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer
Ann. Onc., June 1, 2009; 20(6): 993 - 999.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. F. Leary, W. M. Hanna, M. J. van de Vijver, F. Penault-Llorca, J. Ruschoff, R. Y. Osamura, M. Bilous, and M. Dowsett
Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients
J. Clin. Oncol., April 1, 2009; 27(10): 1694 - 1705.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Lipton, K. Leitzel, H. A. Chaudri-Ross, D. B. Evans, S. M. Ali, L. Demers, P. Hamer, S. Brown-Shimer, K. Pierce, V. Gaur, et al.
Serum TIMP-1 and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen in Metastatic Breast Cancer
J. Clin. Oncol., June 1, 2008; 26(16): 2653 - 2658.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
M. Dowsett
Factors Predicting Response and Resistance to Endocrine Therapy of Breast Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 14 - 17.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. F. Shariat, K. Bensalah, J. A. Karam, C. G. Roehrborn, A. Gallina, Y. Lotan, K. M. Slawin, and P. I. Karakiewicz
Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer
Clin. Cancer Res., September 15, 2007; 13(18): 5377 - 5384.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Bartsch, C. Wenzel, G. Altorjai, U. Pluschnig, R. M. Mader, M. Gnant, R. Jakesz, M. Rudas, C. C. Zielinski, and G. G. Steger
Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment
Clin. Cancer Res., August 1, 2007; 13(15): 4435 - 4439.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. H.C. Bramwell, G. S. Doig, A. B. Tuck, S. M. Wilson, K. S. Tonkin, A. Tomiak, F. Perera, T. A. Vandenberg, and A. F. Chambers
Serial plasma osteopontin levels have prognostic value in metastatic breast cancer.
Clin. Cancer Res., June 1, 2006; 12(11): 3337 - 3343.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 721 - 747.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. M. Sieuwerts, M. E. Meijer-van Gelder, M. Timmermans, A. M.A.C. Trapman, R. R. Garcia, M. Arnold, A. J.W. Goedheer, H. Portengen, J. G.M. Klijn, and J. A. Foekens
How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study
Clin. Cancer Res., October 15, 2005; 11(20): 7311 - 7321.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
Ann. Onc., October 1, 2005; 16(10): 1569 - 1583.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. De Laurentiis, G. Arpino, E. Massarelli, A. Ruggiero, C. Carlomagno, F. Ciardiello, G. Tortora, D. D'Agostino, F. Caputo, G. Cancello, et al.
A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4741 - 4748.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. P.H.M. Jansen, J. A. Foekens, I. L. van Staveren, M. M. Dirkzwager-Kiel, K. Ritstier, M. P. Look, M. E. Meijer-van Gelder, A. M. Sieuwerts, H. Portengen, L. C.J. Dorssers, et al.
Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling
J. Clin. Oncol., February 1, 2005; 23(4): 732 - 740.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Zhu, L. W. C. Chow, W. T. Y. Loo, X.-Y. Guan, and M. Toi
Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial
Clin. Cancer Res., July 15, 2004; 10(14): 4639 - 4644.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. Ellis
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
Oncologist, June 3, 2004; 9(suppl_3): 20 - 26.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein
Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. Altundag and O. Altundag
Superiority of Letrozole Over Tamoxifen in the First-Line Treatment of Metastatic Breast Cancer Patients With Normal Serum HER-2/neu Levels: Question of Tamoxifen Resistance
J. Clin. Oncol., December 15, 2003; 21(24): 4656 - 4656.
[Full Text] [PDF]


Home page
JCOHome page
A. Lipton, K. Leitzel, L. Demers, H.A. Harvey, S.M. Ali, H.A. Chaudri-Ross, P. Wyld, C. Brady, and W. Carney
In Reply:
J. Clin. Oncol., December 15, 2003; 21(24): 4657 - 4657.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C. P. Price
Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer
Clin. Chem., October 1, 2003; 49(10): 1579 - 1598.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
G. Konecny, M. Pegram, and D. J. Slamon
RESPONSE: Re: Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
J Natl Cancer Inst, September 17, 2003; 95(18): 1418 - 1418.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online